Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy
05 4월 2022 - 3:45PM
Medesis Pharma wishes to accelerate the development of its
antinuclear products and provides an update on its strategy
Medesis Pharma wishes to accelerate the
development of its antinuclear
products and provides an update on its
strategy
Montpellier (France), April,
5, 2022 -
8:45am – Medesis Pharma (ISIN:
FR0010844464, Ticker: ALMDP), a pharmaceutical biotechnology
company developing drug candidates with its proprietary buccal
active ingredient delivery technology, Aonys®, publishes an
information note on the three future drugs in development for the
protection of large populations contaminated after a civil or
military nuclear accident.
Three drugs are specifically intended for the
treatment of large populations contaminated or irradiated after a
civil or military nuclear accident. To date, there is no suitable
treatment for a serious nuclear accident. The three products are at
the heart of the issues with the tragic international situation in
Ukraine, raising the possibility of nuclear war. They are also
topical with the recent decisions to maintain the development of
nuclear power plants.
Medesis Pharma's three drug candidates were
developed in collaboration with the French Atomic Energy Commission
(LRT-CEA), which carried out all the studies on animals
contaminated by radionuclides, and with the Armed Forces Biomedical
Research Institute (IRBA) for studies on irradiated animals. Each
of these products is protected by an international patent
registered or in the process of being registered in most nuclear
countries in the world.
The therapeutic activity has been demonstrated,
and a complementary program is necessary with pharmaceutical
development for industrial production and a tolerance study on
healthy volunteers to demonstrate safety before introducing the
products into State emergency stocks.
Funding requests for these 3 programs
have been submitted by Medesis Pharma to the French Defense
Innovation Agency.
NU01:
NanoCaDTPA: Plutonium
decorporationFor more than 40 years, CaDTPA has
been used by repeated slow IV infusion over several weeks. However,
this treatment carried out in a medical environment is suitable for
a few contaminated people (workers in Nuclear Power Plants), but
impossible to implement when several hundred thousand people are
contaminated.NanoCaDTPA (formulation of CaDTPA in the Aonys
microemulsion) makes it possible to obtain the same efficiency of
extraction of Plutonium, but with simple administration in the
mouth, from a bottle stored at room temperature.
NU02: NanoPB
(Prussian Blue):
Cesium
decorporationPrussian Blue has been used for many
years for the extraction of Cesium. It is administered in large
capsules of 500 mg, 18 capsules per day for 2 to 3 months.
Impossible to dissolve, it is almost impossible to give to children
and adolescents and is accompanied by obstinate constipation
resulting in irradiation of the small pelvis. However, Cesium is
fixed preferentially in the muscles and in particular in the heart
muscle causing abnormalities and cardiac pathologies in children
and adolescents.The NanoPB consists of Prussian Blue nanoparticles
synthesized and stabilized in the Aonys microemulsion. It allows to
obtain a decorporation of cesium 3 times faster with 100 times less
Prussian Blue. It is drinkable and suitable for administration at
any age, including infants and children.
NP02: NanoManganeseThe active
ingredient is manganese sulphate in the Aonys microemulsion. This
product prevents and treats the storm of inflammatory cytokines
triggered by irradiation that causes major respiratory and
digestive inflammation responsible for death. Efficacy is observed
if treatment is started within hours of irradiation. It is
administered by mouth and stored in bottles at room
temperature.This product is currently in a Phase II clinical study
in Brazil to treat severe forms of COVID-19 which are also linked
to an inflammatory cytokine storm.
General information about a nuclear
explosion
- During an explosion, a nuclear weapon first generates a ball of
fire, the size of which varies with the power. A 1 kiloton bomb
would thus generate a ball 60 meters in diameter causing damage up
to 2 kilometers around the point of impact. A 1,000-kiloton bomb
would generate a fireball of more than 1 kilometer, the impact of
which could have a radius of up to 20 kilometers.
- Blast effect: the explosion causes a shock wave with a
displacement of an air mass capable of destroying all surrounding
objects. The vacuum created by the moving air then drives strong
winds, similar to a cyclone or tornado;
- Heat: light radiation and its heat, which represent more than a
third of the energy of the bomb, cause fires and burns on
people;
- Radiation: the bomb generates direct radiation at the moment of
its explosion;
- Radioactive pollution that can be carried by the winds over
great distances by radionuclides which are absorbed by the
respiratory and digestive tracts, settle in the tissues, in
particular the lungs, liver, bones and heart, and will never again
be eliminated and will cause cancer 10 to 15 years later.
Product development PlanFor
each of the two decorporation products of Plutonium and Cesium:•
Pharmaceutical CMC development with preparation for industrial
production,• Tolerance study on 50 healthy volunteers treated for
one month.For the radiation protection product already in clinical
development:• Industrial development,• Tolerance study on 50
healthy volunteers for one month.
Deadlines for product registration and
industrial manufacturing:• 18 months for the two decorporation
products• 12 months for the radiation protection productIn
practice, these deadlines can be shortened or extended depending on
whether or not the Medicines Agency and the public authorities
consider it urgent.
À propos de Medesis PharmaPour avancer dans le
traitement des maladies graves dépourvues de traitement efficace,
Medesis Pharma conçoit des candidats médicaments en s’appuyant sur
sa technologie propriétaire Aonys® d’administration de principes
actifs sous forme de nano-gouttelettes par voie buccale qui rend
efficace le delivery des principes actifs dans toutes les cellules,
avec un passage de la Barrière Hémato EncéphaliqueCette approche
innovante est appliquée à de futurs médicaments pour traiter des
maladies majeures dépourvues de traitements efficaces : la Maladie
d’Alzheimer, la Maladie de Huntington, certains cancers résistants
et les inflammations respiratoires sévères comme celles liées à la
COVID-19. Medesis Pharma développe également des traitements dédiés
aux populations irradiées après un accident nucléaire civil ou
militaire.Société biopharmaceutique française implantée près de
Montpellier, Medesis Pharma est à l’origine de 15 publications
scientifiques, détient 11 brevets internationaux, fruits de 17
années de recherche et se consacre plus particulièrement
aujourd’hui à 4 projets qui rentrent en Phase II clinique dans le
domaine des maladies neurodégénératives et du traitement de la
Covid-19. Reconnue mondialement, Medesis Pharma travaille par
ailleurs sur de nouvelles applications de sa technologie en
partenariat avec des laboratoires de recherche publics (CNRS, CEA,
IRBA), des centres hospitaliers universitaires majeurs en France,
au Canada et aux États-Unis ainsi que des acteurs privés, comme
Transgene.Les actions de Medesis Pharma sont cotées sur Euronext
Growth Paris. FR0010844464 – ALMDP
MEDESIS PHARMATessa Olivato Tel: +33 4 67 03 03
96contact@medesispharma.com
CALYPTUSMarie CalleuxTel : +33 1 53 65 68
66medesispharma@calyptus.net
Pour plus d’information : www.medesispharma.com
- Decorporation-nucleaire_EN_20220405
Medesis Pharma (EU:ALMDP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medesis Pharma (EU:ALMDP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024